Health News

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

Read more

Filed under: Pharmacy News
Tags: Drug, male, Pharmacy

Related posts

• VIVUS Initiates Open Label Safety Study Of Avanafil For Erectile Dysfunction (0)
  VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, announced that it has initiated an open label safety study (TA-314) with its investigational drug, avanafil, in males with erectile dysfunction (ED). Read more [tags] Pharmacy News [/tags]
  
  
• Vigor-25 contains hidden drug ingredient, warns FDA (0)
  The U.S. Food and Drug Administration says Vigor-25, a product marketed as a natural dietary supplement to enhance male sexual performance, should not be purchased or used because it contains sildenafil, the active ingredient in the prescription drug Viagra. Read more [tags] Pharmacy News [/tags]
  
  
• Vantia Therapeutics’ Lead Candidate VA106483 Enters Phase IIb Trial For Nocturia (0)
  Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the [...]
  
  
• Taiwanese hemophiliacs infected by HIV-contaminated medications petition US Supreme Court (0)
  Baum Hedlund announces that Taiwanese hemophiliacs infected by HIV-contaminated medications have petitioned the United States Supreme Court to allow their claims to proceed in California. Their suits contend that California-based defendants illegally used paid plasma donors at high risk for transmitting blood-borne diseases (i.v. drug users, prisoners, and promiscuous urban gay males) to make injected [...]
  
  
• Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses (0)
  At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports. Read more [tags] Pharmacy News [/tags]